Document is current
Any future updates will be listed below
-
Authors
Helbo, Thomas https://orcid.org/0009-0008-2272-7557
Hamm, Sebastian Rask https://orcid.org/0000-0002-2583-3442
Roed, Anna Katrine Haslund https://orcid.org/0009-0001-0715-4403
Gustafsson, Finn https://orcid.org/0000-0003-2144-341X
Sørensen, Søren Schwartz https://orcid.org/0000-0001-5898-8048
Perch, Michael https://orcid.org/0000-0001-9740-1246
Kiim, Kristian Schaumburg https://orcid.org/0000-0003-4212-4936
Andersen, Åse Bengård https://orcid.org/0000-0003-4779-7603
Suarez-Zdunek, Moises Alberto https://orcid.org/0000-0003-0772-1049
Nielsen, Susanne Dam https://orcid.org/0000-0001-6391-7455
- License Information
-
More Information
Article History
Received: 8 May 2025
Accepted: 25 May 2026
First Online: 6 June 2026
Declarations
:
: TH: No conflicts of interest. SRH: No conflicts of interest. AKHR: No conflicts of interest. MASZ: No conflicts of interest. FG: Advisor at Pfizer, Abbott, Ionis, Alnylam, Bayer, Astra-Zeneca, AdjuCor, and FineHeart and speaker at Novartis, all outside the current work. SSS: Advisory board fee from Amicus, consulting fee from Novo both unrelated to this manuscript and fees paid to the hospital. MP: Has received unrestricted research grants from the PulmonX and Therakos and reports advisory board activity for Ryme Medical, Takeda, TFF and Zambon, all unrelated to this manuscript. KSK: Has received research grants from the Novo Nordisk Foundation and is a paid speaker for Intuitive Surgery, both unrelated to this manuscript. ÅBA: No conflicts of interest. SDN: Has received unrestricted research grants from the Novo Nordisk Foundation, Svend Andersen Fonden, Kirsten og Freddy Johansens Fond, the Independent Research Fund Denmark, and reports advisory board activity for Gilead Sciences, Takeda and GlaxoSmithKline/ViiV Healthcare, all unrelated to this manuscript.
